A 58-year-old woman with metastatic breast cancer is evaluated on hospital day 3. She was … — USMLE Step 3

A $58$ -year-old woman with metastatic breast cancer is evaluated on hospital day $3$ . She was initially admitted for acute confusion, severe constipation, and profound lethargy. Laboratory studies on admission showed a corrected serum calcium level of $14.8$ mg/dL. She was promptly treated with aggressive intravenous normal saline, subcutaneous calcitonin, and a single dose of intravenous pamidronate.

Today, her mental status is markedly improved, and she is alert and oriented. Vital signs are temperature $37.0^{\circ}$ C ( $98.6^{\circ}$ F), blood pressure $122/78$ mmHg, heart rate $84$ /min, and respiratory rate $16$ /min.

Current laboratory studies show:
Blood urea nitrogen: $18$ mg/dL
Serum creatinine: $1.1$ mg/dL
Corrected serum calcium: $11.2$ mg/dL

Which of the following is the most appropriate next step in the pharmacologic management of this patient?

A
Administer a second dose of intravenous pamidronate
B
Continue the current regimen with no modifications
Discontinue subcutaneous calcitoninAnswer
D
Initiate oral glucocorticoids
E
Transition the intravenous normal saline to 5% dextrose in water

Answer

Discontinue subcutaneous calcitonin

The correct step is to discontinue the rapid-acting agent due to pharmacodynamic tachyphylaxis. In the acute management of severe hypercalcemia (calcium >

14.0

mg/dL), initial therapy consists of aggressive isotonic saline hydration, calcitonin, and an intravenous bisphosphonate. Calcitonin provides a rapid reduction in serum calcium within

4

6

hours. However, its efficacy is transient, and tachyphylaxis (rapid downregulation of calcitonin receptors on osteoclasts) predictably develops within

48

72

hours. By hospital day

3

, the bisphosphonate (which takes

2

4

days to reach its maximum calcium-lowering effect) begins to provide sustained control. Therefore, the standard of care dictates discontinuing calcitonin after

48

hours to avoid unnecessary continuation of an ineffective drug.

Step-by-Step Solution

Evaluate the current duration of therapy and the patient's clinical trajectory.

The patient has been receiving calcitonin and a bisphosphonate for approximately 48 to 72 hours, and her hypercalcemia is significantly improving.

Different hypercalcemia medications possess distinct onset and duration profiles that dictate strict monitoring and discontinuation timelines.

Assess the pharmacodynamics of calcitonin.

Calcitonin acts rapidly (within 4 to 6 hours) but is limited by the development of tachyphylaxis within 48 to 72 hours due to receptor downregulation.

Identifying the onset of tachyphylaxis dictates the safe and appropriate discontinuation of the drug to prevent unnecessary administration.

Assess the pharmacodynamics of the administered bisphosphonate.

Pamidronate takes 2 to 4 days to reach peak efficacy, which perfectly overlaps with the waning effect of calcitonin.

Confirming that the long-acting agent is taking effect ensures that the patient will maintain calcium control after the rapid-acting agent is stopped.

Key Concept

In the management of severe hypercalcemia, calcitonin is utilized for rapid serum calcium reduction but must be systematically discontinued after 48 to 72 hours due to the development of tachyphylaxis, at which point long-acting bisphosphonates achieve peak therapeutic effect.

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic